Chemomab Therapeutics Ltd.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2022 | -76.3% | -76.3% | -64.2% |
| FY2023 | -142.5% | -142.5% | -109.3% |
| FY2024 | -103.0% | -103.0% | -82.2% |
| FY2025 | -72.9% | -72.9% | -65.1% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2022 | -76.3% | -76.3% | -64.2% |
| FY2023 | -142.5% | -142.5% | -109.3% |
| FY2024 | -103.0% | -103.0% | -82.2% |
| FY2025 | -72.9% | -72.9% | -65.1% |